CHD1 is a synthetic lethal vulnerability in MYC-driven breast cancer

Model for the effect of CHD1 KD in MYC-driven breast cancer. By analysing two unbiased genome-wide screens, we identify and validate the chromatin remodeler CHD1 as a synthetic lethal vulnerability in a xenograft model of MYC-driven breast cancer.

Authors: Cho B, Furlan G, Lin P, Shen M, Mittal K, Mazzanti A, Penn L, Ramalho-Santos M.

bioRxiv, 2025.08.14.670376; doi: 10.1101/2025.08.14.670376

PMID:

Abstract: The MYC transcription factor is a key regulator of growth during development and a potent cancer driver when its expression is dysregulated. Strategies to inhibit MYC oncogenic activity would mark a significant advance, but decades of efforts to target MYC directly have not been fruitful. Understanding how MYC drives transformation and tumor growth may provide new therapeutic avenues in a variety of cancers. By intersecting two independent genome-wide screens, we identified loss of the chromatin remodeler Chromodomain-Helicase DNA-binding 1 (CHD1) as a potential synthetic lethal target in MYC-driven breast cancer. Knockdown of CHD1 in a xenograft model of MYC-driven breast cancer suppresses tumor growth in vivo. In tissue culture models, we found that knockdown of CHD1 suppresses cell proliferation and induces cell death, specifically when MYC is overexpressed. Mechanistically, we found that CHD1 is required to maintain an open chromatin landscape and a transcriptional program associated with cancer progression in MYC overexpressing breast cells. Follow-up experiments indicate that this synthetic lethality may arise from nucleolar stress and p53 activation. These findings provide new insights on the chromatin-level regulation of MYC-driven breast cancer and uncover CHD1 as a novel synthetic vulnerability and potential therapeutic target.